ArticleFrontiers in immunology2025
Glycolysis-related radiosensitivity signature for predicting radiotherapy response in breast cancer.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Glucose metabolic reprogramming: a novel strategy to enhance radiotherapy response to triple-negative breast cancer.Frontiers in public health · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study investigates the influence of glycolytic activity on the efficacy of radiotherapy in breast cancer (BRCA) patients, aiming to develop a glycolysis-related radiosensitivity signature to predict radiotherapy efficacy. Methods: We categorized BRCA patients into low and high glycolysis groups using ssGSEA analysis based on 200 glycolysis-related genes. Univariate and multivariate Cox regression analyses, were used to construct a radiosensitivity signature. Immune cell infiltration and pathway enrichment analyses were conducted using ESTIMATE and CIBERSORT methods. The TIDE algorithm and pRRophetic algorithm were employed to predict responses to radiotherapy. Radioresistant BRCA cells were examined using CCK-8 assay. Key genes identified in the radiosensitivity signature were validated Results: Our analyses revealed that patients in the low-glycolysis group exhibited enhanced sensitivity to radiotherapy, suggesting that glycolytic activity is a critical determinant of radiotherapy. Subsequently, we developed a four-gene radiosensitivity signature that effectively stratified patients into radiosensitive (RS) and radioresistant (RR) groups. Survival analysis revealed that radiotherapy significantly improves outcomes in the RS group but not in the RR group. Immune infiltration analysis indicated that the RS group correlates with an active immune landscape, as evidenced by lower TIDE scores and higher responsiveness to immune checkpoint inhibitors. Notably, patients in the RS group with high PD-L1 expression showed significantly better outcomes, associated with increased immune cell infiltration. Conclusion: Our study establishes glycolytic activity as a promising predictor of radiotherapy efficacy in BRCA patients and develops a novel radiosensitivity signature with potential clinical utility in guiding personalized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.